AR032984A1 - Vacuna contra herpesvirus equinos - Google Patents
Vacuna contra herpesvirus equinosInfo
- Publication number
- AR032984A1 AR032984A1 ARP020100906A ARP020100906A AR032984A1 AR 032984 A1 AR032984 A1 AR 032984A1 AR P020100906 A ARP020100906 A AR P020100906A AR P020100906 A ARP020100906 A AR P020100906A AR 032984 A1 AR032984 A1 AR 032984A1
- Authority
- AR
- Argentina
- Prior art keywords
- ehv
- vaccine
- inactivated
- equine
- equinos
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
- C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
- C07K16/087—Herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/27—Equine rhinopneumonitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
- C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C12N2760/16163—Methods of inactivation or attenuation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/812,720 US6803041B2 (en) | 2001-03-20 | 2001-03-20 | Equine herpesvirus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032984A1 true AR032984A1 (es) | 2003-12-03 |
Family
ID=25210428
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100906A AR032984A1 (es) | 2001-03-20 | 2002-03-13 | Vacuna contra herpesvirus equinos |
| ARP130101929 AR091235A2 (es) | 2001-03-20 | 2013-05-31 | Vacuna contra herpesvirus equinos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101929 AR091235A2 (es) | 2001-03-20 | 2013-05-31 | Vacuna contra herpesvirus equinos |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US6803041B2 (https=) |
| EP (2) | EP1372712B1 (https=) |
| JP (2) | JP4177112B2 (https=) |
| KR (1) | KR100840525B1 (https=) |
| AR (2) | AR032984A1 (https=) |
| AT (1) | ATE392903T1 (https=) |
| CA (1) | CA2441292C (https=) |
| CY (1) | CY1108200T1 (https=) |
| DE (1) | DE60226218T2 (https=) |
| DK (2) | DK1372712T3 (https=) |
| ES (2) | ES2428664T3 (https=) |
| MX (1) | MXPA03008287A (https=) |
| NZ (1) | NZ529012A (https=) |
| PT (1) | PT1372712E (https=) |
| WO (1) | WO2002074335A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6803041B2 (en) * | 2001-03-20 | 2004-10-12 | Boehringer Ingelheim Vetmedica, Inc. | Equine herpesvirus vaccine |
| JP2005075752A (ja) * | 2003-08-29 | 2005-03-24 | Nippon Inst For Biological Science | 豚繁殖・呼吸障害症候群用ワクチン製剤 |
| US7572620B2 (en) | 2005-01-11 | 2009-08-11 | Wisconsin Alumni Research Foundation | H3 equine influenza A virus |
| WO2007051763A1 (en) * | 2005-11-01 | 2007-05-10 | Intervet International B.V. | Prime boost vaccine for the protection of equines against equine influenza |
| US9642908B2 (en) | 2008-07-30 | 2017-05-09 | University Of Kentucky Research Foundation | Equine disease model for herpesvirus neurologic disease and uses thereof |
| CN107365751B (zh) | 2008-12-16 | 2021-07-09 | 纳米医疗公司 | 流感疫苗的生产 |
| WO2010144797A2 (en) | 2009-06-12 | 2010-12-16 | Vaccine Technologies, Incorporated | Influenza vaccines with enhanced immunogenicity and uses thereof |
| PL2569007T3 (pl) * | 2010-05-11 | 2016-04-29 | Intervet Int Bv | Szczepionka przeciwko Mycoplasma Hyopneumoniae, odpowiednia do podawania w obecności przeciwciał pochodzących od matki |
| SI3542819T1 (sl) * | 2013-05-14 | 2021-11-30 | Zoetis Services Llc | Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide |
| JP6560056B2 (ja) * | 2015-08-07 | 2019-08-14 | ウィスコンシン アルムニ リサーチ ファンデイション | Ｈ３型ウマａ型インフルエンザウイルス |
| ES2991988T3 (es) | 2017-10-30 | 2024-12-05 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica |
| JP2018088928A (ja) * | 2018-02-13 | 2018-06-14 | ウィスコンシン アルムニ リサーチ ファンデイション | Ｈ３型ウマａ型インフルエンザウイルス |
| US20250114447A1 (en) * | 2021-08-06 | 2025-04-10 | Intervet Inc. | Vaccine for equine herpesvirus |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3920811A (en) * | 1972-12-22 | 1975-11-18 | Cutter Lab | Adjuvant compositions |
| US4110433A (en) | 1976-04-23 | 1978-08-29 | Philips Roxane, Inc. | Equine rhinopneumonitis virus |
| US4083958A (en) | 1976-09-13 | 1978-04-11 | The University Of Kentucky Research Foundation | Inactivated equine rhinopneumonitis virus vaccine and use thereof |
| US4225582A (en) | 1979-03-08 | 1980-09-30 | The University Of Illinois Foundation | Vaccine for equine rhinopneumonitis |
| US4500513A (en) * | 1979-05-15 | 1985-02-19 | Miles Laboratories, Inc. | Influenza vaccine production in liquid cell culture |
| US4509949A (en) | 1983-06-13 | 1985-04-09 | The B. F. Goodrich Company | Water thickening agents consisting of copolymers of crosslinked acrylic acids and esters |
| EP0163696B1 (en) | 1983-11-14 | 1992-11-25 | Columbia Laboratories, Inc. | Use of a bioadhesive |
| US5084271B1 (en) | 1984-09-11 | 1997-08-05 | Univ Melbourne | Vaccine for equine herpesvirus |
| US4758641A (en) | 1987-02-24 | 1988-07-19 | The B F Goodrich Company | Polycarboxylic acids with small amount of residual monomer |
| NZ224422A (en) | 1987-05-05 | 1990-11-27 | Molecular Eng Ass | Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid |
| US5221722A (en) | 1988-11-28 | 1993-06-22 | The B. F. Goodrich Company | Crosslinked polyacrylic acid |
| US5292653A (en) * | 1989-09-27 | 1994-03-08 | Novagene, Inc. | Equine herpesvirus 1 tk mutants |
| US6025181A (en) * | 1990-07-06 | 2000-02-15 | University Court Of The University Of Glasgow | Equine herpesvirus-4TK mutant |
| GB9014950D0 (en) * | 1990-07-06 | 1990-08-29 | Univ Glasgow | Ehv-4 glycoprotein vaccine |
| EP0560776B1 (en) * | 1990-08-01 | 2000-02-09 | Research Corporation Technologies, Inc. | The gene encoding equine herpesvirus type 1 glycoprotein d, its gene product, antibodies and their uses |
| US5462734A (en) * | 1990-11-02 | 1995-10-31 | Wisconsin Alumni Research Foundation | Bovine herpesvirus vaccine and method of using same |
| EP0532833A1 (en) | 1991-05-28 | 1993-03-24 | Miles Inc. | Vaccine for equine rhinopneumonitis |
| US5922327A (en) | 1992-06-01 | 1999-07-13 | The University Of Melbourne | Equine herpes virus glycoproteins |
| US6193983B1 (en) * | 1992-06-01 | 2001-02-27 | The University Of Melbourne | Equine herpesvirus glycoproteins |
| US6225111B1 (en) * | 1992-08-07 | 2001-05-01 | Schering Plough Veterinary Corp. | Recombinant equine herpesviruses |
| AUPN720195A0 (en) * | 1995-12-18 | 1996-01-18 | University Of Melbourne, The | Equine rhinovirus 1 proteins |
| FR2751226B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies du cheval |
| US5853715A (en) * | 1996-08-16 | 1998-12-29 | Bayer Corporation | Cross-protective equine herpesvirus preparations and method of making and using the same |
| JP2002504227A (ja) | 1997-03-12 | 2002-02-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | クロマトグラフィーカラムの末端部材 |
| US5891705A (en) * | 1997-04-08 | 1999-04-06 | Pentose Pharmaceuticals, Inc. | Method for inactivating a virus |
| EP0978286A1 (en) | 1998-08-07 | 2000-02-09 | Bayer Corporation | Cross-protective equine herpesvirus preparations and method of making and using the same |
| US6803041B2 (en) * | 2001-03-20 | 2004-10-12 | Boehringer Ingelheim Vetmedica, Inc. | Equine herpesvirus vaccine |
-
2001
- 2001-03-20 US US09/812,720 patent/US6803041B2/en not_active Expired - Lifetime
-
2002
- 2002-01-23 EP EP02713437A patent/EP1372712B1/en not_active Expired - Lifetime
- 2002-01-23 DE DE60226218T patent/DE60226218T2/de not_active Expired - Lifetime
- 2002-01-23 CA CA2441292A patent/CA2441292C/en not_active Expired - Lifetime
- 2002-01-23 KR KR1020037012273A patent/KR100840525B1/ko not_active Expired - Lifetime
- 2002-01-23 ES ES08150506T patent/ES2428664T3/es not_active Expired - Lifetime
- 2002-01-23 DK DK02713437T patent/DK1372712T3/da active
- 2002-01-23 AT AT02713437T patent/ATE392903T1/de active
- 2002-01-23 MX MXPA03008287A patent/MXPA03008287A/es active IP Right Grant
- 2002-01-23 ES ES02713437T patent/ES2305220T3/es not_active Expired - Lifetime
- 2002-01-23 NZ NZ529012A patent/NZ529012A/en not_active IP Right Cessation
- 2002-01-23 EP EP08150506.7A patent/EP1923071B1/en not_active Expired - Lifetime
- 2002-01-23 JP JP2002573042A patent/JP4177112B2/ja not_active Expired - Lifetime
- 2002-01-23 DK DK08150506.7T patent/DK1923071T3/da active
- 2002-01-23 PT PT02713437T patent/PT1372712E/pt unknown
- 2002-01-23 WO PCT/US2002/001644 patent/WO2002074335A2/en not_active Ceased
- 2002-03-13 AR ARP020100906A patent/AR032984A1/es unknown
-
2004
- 2004-07-23 US US10/897,984 patent/US7226604B2/en not_active Expired - Lifetime
-
2007
- 2007-04-26 US US11/789,919 patent/US20070196390A1/en not_active Abandoned
- 2007-05-14 JP JP2007127589A patent/JP4668951B2/ja not_active Expired - Lifetime
-
2008
- 2008-07-17 CY CY20081100745T patent/CY1108200T1/el unknown
-
2013
- 2013-05-31 AR ARP130101929 patent/AR091235A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2441292C (en) | 2012-03-20 |
| DE60226218D1 (de) | 2008-06-05 |
| CA2441292A1 (en) | 2002-09-26 |
| JP4668951B2 (ja) | 2011-04-13 |
| ES2428664T3 (es) | 2013-11-08 |
| ATE392903T1 (de) | 2008-05-15 |
| EP1923071B1 (en) | 2013-06-19 |
| DE60226218T2 (de) | 2009-05-28 |
| US20050084502A1 (en) | 2005-04-21 |
| US7226604B2 (en) | 2007-06-05 |
| DK1923071T3 (da) | 2013-08-26 |
| KR100840525B1 (ko) | 2008-06-24 |
| EP1923071A1 (en) | 2008-05-21 |
| KR20030085028A (ko) | 2003-11-01 |
| JP2004525923A (ja) | 2004-08-26 |
| EP1372712B1 (en) | 2008-04-23 |
| CY1108200T1 (el) | 2014-02-12 |
| AR091235A2 (es) | 2015-01-21 |
| PT1372712E (pt) | 2008-05-29 |
| US20030206924A1 (en) | 2003-11-06 |
| DK1372712T3 (da) | 2008-08-04 |
| WO2002074335A3 (en) | 2003-07-17 |
| EP1372712A2 (en) | 2004-01-02 |
| US6803041B2 (en) | 2004-10-12 |
| WO2002074335A2 (en) | 2002-09-26 |
| NZ529012A (en) | 2005-08-26 |
| JP2007197470A (ja) | 2007-08-09 |
| ES2305220T3 (es) | 2008-11-01 |
| MXPA03008287A (es) | 2004-10-28 |
| US20070196390A1 (en) | 2007-08-23 |
| JP4177112B2 (ja) | 2008-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091235A2 (es) | Vacuna contra herpesvirus equinos | |
| PH12019501766A1 (en) | Porcine coronavirus vaccines | |
| WO2022221440A8 (en) | Influenza-coronavirus combination vaccines | |
| MX2023000411A (es) | Vacuna combinada de sars-cov-2 e influenza. | |
| DK1216053T3 (da) | Influenzavaccine | |
| BR9705009A (pt) | Vírus da síndrome porcina reprodutiva e respiratória de vida atenuada processo para preparação do mesmo vacina para a proteção de porcos contra a infecção pelo vírus e processo para preparação da vacina | |
| WO2006068663A3 (en) | Vaccine compositions for treating coronavirus infection | |
| AR056566A1 (es) | Vacunas y procedimientos para tratar la gripe canina | |
| JP2007197470A5 (https=) | ||
| CO6361950A2 (es) | Composiciones, vacunas y metodos del virus del herpes del ganado bovino -1 | |
| ATE547118T1 (de) | Rekombinanter koi-herpesvirus (khv) oder cyprinid-herpesvirus 3 (cyhv-3) und impfstoff zur prävention einer von khv/cyhv-3 bei cyprinus carpio carpio oder cyprinus carpio koi verursachten erkrankung | |
| MXPA02001223A (es) | Proteinas derivadas del virus de sindrome de mancha blanca y usos de las mismas. | |
| AR029954A1 (es) | Uso de cepas de parapoxvirus ovis para la fabricacion de medicamentos antivirales y medicamentos contra el cancer | |
| ES2141093T3 (es) | Herpesvirus equinos (ehv) que contienen adn ajeno, procedimiento para su obtencion y su empleo en vacunas. | |
| AR040601A1 (es) | Mutantes ehv negativos de gm sin elementos heterologos | |
| EA200301151A1 (ru) | Вакцина против натуральной оспы | |
| WO2001074386A3 (en) | Cold-adapted equine influenza viruses | |
| MX2024000330A (es) | Vacuna universal para virus de influenza en base a la proteina m2 tetramerica incorporada en nanodiscos. | |
| ES2063897T3 (es) | Vacuna contra el virus del colera porcino y diagnostico. | |
| TW200617166A (en) | Multivalent avian influenza vaccines | |
| CL2020002876A1 (es) | Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420) | |
| AR031599A1 (es) | Vacunas para el virus herpes equino tipo 1: virus que hospeda mutaciones dentro del gen inmediato precoz | |
| AR056753A1 (es) | Vacuna de primera dosis -refuerzo para la proteccion de equinos contra la influenza equina | |
| WO2025168804A8 (en) | A vaccine for protecting a pregnant swine against african swine fever | |
| MX2025014589A (es) | Partículas similares al virus para el tratamiento de sars-cov2 |